TY  - JOUR
T1  - Karbamazepin monoterapisine yanıt alınamayan parsiyel epilepsi hastalarında levetiracetam veya zonisamid ek tedavilerinin karşılaştırılması
TT  - Comparison of levetiracetam or zonicamide additional treatments in partial epilepsy diseases which karbamazepine monotherapy is not responded
AU  - Acar, Türkan
AU  - Öztekin, Mehmet Fevzi
AU  - Öztekin, Neşe
PY  - 2018
DA  - December
DO  - 10.21601/ortadogutipdergisi.365144
JF  - Ortadoğu Tıp Dergisi
JO  - omj
PB  - MEDİTAGEM Ltd. Şti.
WT  - DergiPark
SN  - 2548-0251
SP  - 511
EP  - 515
VL  - 10
IS  - 4
LA  - tr
AB  - Giriş ve Amaç: Parsiyel epilepsi en sık görülen nöbet tipi olup bazı hastalardamonoterapi ve hatta politerapiye rağmen yeterli nöbet kontrolüsağlanamayabilir. Bu çalışmadaki amacımız karbamazepin monoterapisi ile nöbetkontrolü sağlanamamış hastalarda levetirasetam veya zonisamid eklemetedavilerinin etkinlik ve yan etki bakımından karşılaştırılması hedeflenmiştir.Gereç ve Yöntem: 18-54 yaş arası, en az 1 yıldır karbamazepinmonoterapisi ile takip edilen 32 hasta çalışmaya alındı. Bu hastaların 16’sınazonisamid, 16’sına levetirasetam eklendi. Hastalar ekleme tedavisi sonrasısabit titrasyonda tutulacak şekilde 3 ay boyunca izlendi.Bulgular: Zonisamid eklenen grubun yaş ortalaması 33,4±10,6 (7erkek, 9 kadın)iken levetirasetam grubunda 35,7±11,5 (8 erkek, 8 kadın) idi. Toplam nöbetsayıları bakımından 3 aylık izlem süresi değerlendirildiğinde her iki grup arasındaetkinlik ve yan etki bakımından istatistiksel olarak anlamlı farksaptanmamıştır (p=0,377). Sonuç: Parsiyel nöbetlerin ekleme tedavilerinde levetirasetam veya zonisamidbenzer oranda etkin olup nöbet kontrolü sağlanamayan hastalarda yan etki profilininde az olması nedeniyle kullanılabilir.
KW  - Levetirasetam
KW  - zonisamid
KW  - parsiyel epilepsi
N2  - Background and Aims: Partial epilepsy is the most commontype of seizure and in some patients sufficient seizure control may not beachieved despite monotherapy and even polytherapy. Our aim in this study was tocompare the efficacy and side effects of levetiracetam or zonisamide add-ontreatments in patients without seizure control with carbamazepine monotherapy.Material and Method: Thirty-two patients aged 18-54 yearswho were followed for at least 1 year by carbamazepine monotherapy wereincluded in the study. Zonisamide was added to 16 of these patients, andlevetiracetam was added to 16 of these patients. Patients were monitored for 3months to be held at constant titration after the insertion therapy.Results: The mean age of the group to which zonisamide was added was33.4 ± 10.6 (7 males, 9 females) while the levetiracetam group had 35.7 ± 11.5(8 males, 8 females). When 3-month follow-up period was evaluated in terms oftotal number of seizures, there was no statistically significant differencebetween the two groups in terms of efficacy and side effects (p = 0,377).Conclusion: Levetiracetam or zonisamide can be used in patientswith partial seizures with similar side effects and fewer side effects inpatients with seizure control.
CR  - 1.	Blume WT, Luders HO, Mizrahi E, Tassinari C, van Emde BW, Engel Jr. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia, 2001;42:1212-8.
2.	Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia, 1993;34:453-68.
3.	Lavados J, Germain I, Morales A, Campero M, Lavados P. A descriptive study of epilepsy in the district of EL Salvador, Chile, 1984-1988. Acta Neurol Scand, 1992;91:718-29.
4.	Joensen P. Prevalence, incidence and classification of epilepsy in Faroes. Acta Neurol Scand, 1986;74:150-5.
5.	Steinlein O.K. Genes and mutations in idiopathic epilepsy. Am J Med Genet, 2001;106:136-45.
6.	French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of new antiepileptic drugs, I: Treatment of new onset epilepsy: Report of TTA and OSS subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia, 2004;45:401-9.
7.	Epilepsi. Bora İ, Yeni S.N, Gürses C. Nobel Tıp Kitapevleri. 2008.
8.	Baulac M, Leppik I.E. Efficacy and safety od adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res, 2007;75:75-83.
9.	Seino M, Fıjitani B. Zonisamide, clinical efficacy and use in epilepsy. In: Levy R.H (Ed), Antiepileptic drugs. Lippincott, Williams, Wilkins, Philadelphia, 2002;5:885-91.
10.	Thomas G, McCabe P.H. Clinical use of zonisamide in generalized seizure disorders. Epilepsia 2005;46 (suppl.7):2294.
11.	Conry J.A, Ramsey R.E, Vossler D, Glauser T.A. Efficacy and safety of zonisamide as adjunctive therapy for primary generalized epilepsy. Epilepsia 2005;46(suppl.7):2350.
12.	O’Rourke D, Flynn C, White M, Doherty C, Delanty N. Potential efficacy of zonisamide in refractory juvenile myoclonic epilepsy. Epilepsia 2005;46(suppl.6):301.
13.	Welty T.E, Kuzniecky R, Faught E. Outcome of using new AED in juvenile myoclonic epilepsy. Neurology 2003;60(suppl.1):147.
14.	Sackellares J.C, Ramsay R.E, Wilder B.J, Browne T.R, Shellenberger M.K. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia, 2004;45(6):610-7.
15.	Ben-Menachem E, Falter U. and for the European Levetiracetam, Study Group, Efficacy and tolerability of levetiracetam, 3000 mg/d in patients with refractory partial seizures:a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia, 2000;41:1276–83.
16.	Chadwick D.W, Marson A.G. zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. 2005, Issue 4, CD001416.
17.	Faught E, Ayala R, Montouris G, Leppik I. Randomize controlled trial of zonisamide for the treatment of refractory partial onset seizures. Neurology 2001;57:1774-9.  
18.	Harden C. Safety profile of levetiracetam. Epilepsia, 2001;42(4):36–9.
UR  - https://doi.org/10.21601/ortadogutipdergisi.365144
L1  - https://dergipark.org.tr/tr/download/article-file/584438
ER  -